Physician profile
Rajeeve Subbiah
NPI 1619280237
$5,409.16
in general payments reported to CMS, 2019-2025
31 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $428 · 2021: $442 · 2022: $778 · 2023: $908 · 2024: $927 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,867 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,866.65 |
| Education | $119.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,015.23 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $482.51 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $403.35 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $379.09 | 2019-2025 | Opsumit, Uptravi |
| Pfizer INC. | $364.77 | 2019-2025 | |
| Amgen INC. | $302.83 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $294.46 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $255.94 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $252.95 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $244.25 | 2022-2025 | Verquvo, Winrevair |
| Boston Scientific Corporation | $228.14 | 2019-2025 | General - Balloon Catheters, Avvigo Guidance System, Watchman Access System |
| Abiomed | $148.03 | 2022-2025 | Impella |
| Abbott Laboratories | $137.32 | 2023-2025 | Mitraclip, Cardiomems, Aveir |
| Bayer Healthcare Pharmaceuticals INC. | $131.24 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $93.21 | 2023-2024 | Inpefa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $83.07 | 2025 | |
| Medtronic Vascular, INC. | $79.14 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.39 | 2019-2024 | Jardiance |
| Heartflow, INC. | $65.55 | 2023-2025 | Ffrct |
| Esperion Therapeutics, INC. | $50.04 | 2022-2025 | Nexletol |
| Philips North America LLC | $45.34 | 2019 | |
| Amarin Pharma, INC. | $42.57 | 2019 | |
| Acist Medical Systems, INC. | $41.09 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $40.20 | 2019 | |
| Edwards Lifesciences Corporation | $29.53 | 2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $29.50 | 2021 | |
| Inari Medical, INC. | $23.43 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cvrx, INC. | $22.90 | 2024 | Barostim Neo System |
| Inspire Medical Systems, INC. | $19.38 | 2025 | Inspire |
| Cordis US Corp. | $18.25 | 2023 | Radial 360 |
| Glaxosmithkline, LLC. | $15.46 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeeve Subbiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.